



# **MANKIND PHARMA**

## **Financial Analysis Report On**

FINACIAL ANALYSIS REPORT SUBMITTED TO THE  
KARNATAKA UNIVERSITY DHARWAD

IN PARTIAL FULFILMENT OF THE DEGREE OF

**Bachelor Of Commerce**

By

**MAHANTESH. R. PATIL**

REG NO : U02BE21C0031

B. Com. VI Semester

SHREE SHARANA NULIYA CHANDAYYA  
Dr. B.R. AMBEDKAR SMARAK FIRST GRADE COLLEGE,  
HUBBALLI-580020 (U.K.)

Under the Guidance of

**Prof : S. N. MALIPATIL**

( Lecturer )

Dept. of Commerce

**SSNC Dr. B.R.AMBEDKAR COLLEGE**  
**HUIBALLI.**

**2024**



# **MANKIND PHARMA**

## **Financial Analysis Report On**

FINANCIAL ANALYSIS REPORT SUBMITTED TO THE  
KARNATAKA UNIVERSITY DHARWAD

IN PARTIAL FULFILMENT OF THE DEGREE OF

**Bachelor Of Commerce**

By

**MAHANTESH. R. PATIL**

REG NO : U02BE21C0031

B. Com. VI Semester

---

SHREE SHARANA NULIYA CHANDAYYA  
Dr. B.R. AMBEDKAR SMARAK FIRST GRADE COLLEGE,  
HUBBALLI-580020 (U.K.)

---

Under the Guidance of

**Prof : S.N. MALIPATIL**

(Lecturer)

Dept. of Commerce

**SSNC Dr. B.R.AMBEDKAR COLLEGE**  
**HUIBALLI.**

**2024**

**KARNATAKA UNIVERSITY DHARWAD**

DEPARTMENT OF COMMERCE



**CERTIFICATE BY RESEARCH GUIDE**

THIS IS TO CERTIFY THAT PROJECT REPORT ENTITLED "THE STUDY ON ANALYSIS OF FINANCIAL STATEMENT OF MAHIND PHARMA LTD" IS THE BONAFIED WORK CARRIED OUT BY MAIDEN MAHANTESH R PATIL STUDENT OF 6<sup>TH</sup> SEMESTER OF B.COM DEGREE IN COMMERCE DURING THE YEAR 2024 IN PARTIAL FULFILLMENT OF THE REQUIREMENT FOR THE PROJECT WORK THE B.COM IN COMMERCE AND THE PROJECT HAS NOT FORMED THE BASIS FOR THE AWARD OF ANY DEGREE ASSOCIATESHIP, FELLOWSHIP OR ANY OTHER SIMILAR TITLE THE VIEWS AND OPINIONS EXPRESSED IN THIS PROJECT WORK ARE OF THE STUDENT ALONE.

RESEARCH GUIDE

SIR. SHRI S N MALIPATIL

DEPARTMENT OF COMMERCE

SSNC, ARTS AND COMMERCE  
COLLEGE HUBLI

# ARNATAKA UNIVERSITY DHARWAD

DEPARTMENT OF COMMERCE



## CERTIFICATE OF EXAMINER

This is to certify that **MAHANTESH E PATIL**, a Bonafied student of B.com 6<sup>th</sup> Sem project on "A STUDY ON ANALYSES OF FINANCIAL STATEMENT OF **MANIND PHARMA LTD**" has successfully completed the project during the year 2023-24 under the guidance of **SIR. SHRI S N MALIPATIL** for the examination 2024.

It is to further certified that this project is the individual work of the candidate.

  
EXTERNAL EXAMINER  
**S. S. Hiremath**

  
INTERNAL EXAMINER  
**S. N. Malipatil**

Date:

Seal:



# KARNATAKA UNIVERSITY DHARWAD

DEPARTMENT OF COMMERCE



## DECLARATION BY THE COMMERCE STUDENT

I hereby declare that the project report entitled " A **STUDY ON ANALYSIS OF FINANCIAL STATEMENT OF MANKIND PHARMA LTD**" submitted to the Karnataka University Dharwad in partial fulfillment of the requirement for the award of degree of B.COM in project work is my original work and the project has not formed the basis for project work of any degree, associate ship, fellow ship or any other similar title I am responsible for the views and opinions expressed in this project work and these are not expressions of the department guide.

Date:

NAME OF THE RESEARCHER

MAHANTESHGUDA.R.PATIL

Place:

B.COM 6<sup>TH</sup> SEM

## ACKNOWLEDGEMENT

I WOULD LIKE TO THANK MY GUIDE SIR SHRI S N MALIPATIL AND OUR PRINCIPAL SHRI M.D. MATTIMANI FOR GIVING ME A WONDERFUL OPPORTUNITY TO WORK ON THE TOPIC "A STUDY ON ANALYSIS OF FINANCIAL STATEMENT OF (MANKIND PHARMA) LTD". THIS PROJECT HAS HELPED ME IN DOING A LOT RESEARCH AND CAME TO KNOW ABOUT A LOT OF NEW THINGS FOR THIS EXPERIENCE, I AM REALLY THANKFUL. I WOULD ALSO LIKE TO EXTEND MY GRATITUDE TOWARDS MY PARENTS AND MY PROJECT MATES WHO HAVE HELPED ME A LOT IN FINISHING THE PROJECT WITHIN THE GIVEN TIME FRAME AND SECONDLY THANK TO MY FRIENDS WHO HAVE HELPED IN MY PROJECT.

B.COM STUDENT

MAHANTESHGUDA R.PATIL

# INDEX

PAGE NO.	DESCRIPTION	PAGE NUMBER
<b>Unit 1</b>	<b>Interdiction</b>	
14	Report	8
15	Meaning	8
15	Definition	8
15	Importance of report	8
15	Feature of report	8
<b>16</b>	<b>Financial Analysis report</b>	<b>10</b>
16	Meaning	10
16	Definition	10
16	Importance of financial report	10
16	Features of Financial analysis report	11
<b>17</b>	<b>Company Profile</b>	<b>12</b>
17	history	12
17	Services	13
<b>Unit 2</b>	<b>Conceptual Framework</b>	<b>15</b>
24	Title of Report	15
27	Purpose of report	15
29	Objective of the report	15
31	Collection of Data	16
31	Tools and Techniques	16
31	Scope of the report	18
31	Desire output and outcome	18
31	Structure of report	18
31	Limitation of report	20
<b>Unit 3</b>	<b>Analysis and interpretation</b>	<b>21</b>
33	<b>Comparative Statement</b>	<b>21</b>
33	Meaning	21
33	Objective of comparative statement	21
33	<b>Trend Analysis</b>	<b>29</b>
33	Meaning	29
33	Objective	30
33	<b>Ratio analysis</b>	<b>33</b>
33	Meaning	33
33	Objective	33
<b>Unit 4</b>	<b>Summary of report</b>	<b>41</b>
41	Key findings	41
41	Suggestions	41

## LIST OF STATEMENTS & CALCULATIONS

STATEMENT OR CALCULATION NUMBER	DESCRIPTION	PAGE NUMBER
3.1	Comparative Balance 2020-2021	21-22
3.2	Comparative Balance 2021-2022	23-24
3.3	Comparative Balance 2022-2023	25-26
3.4	Comparative Balance 2023-2024	27-28
3.5	Trend Analysis	29
3.6	Balance Sheet of 2020-2024	44-45
3.7	Profit and Loss of 2020-2024	45-46
3.8	Cash Flow of 2020-2024	47

## LIST OF CHARTS

CHARTING NO.	DESCRIPTION	PAGE NO.
3.10	Sales Trend Analysis	30
3.11	Stock Trend Analysis	31
3.12	Profit Before Tax (PBT)	32
3.13	Current Ratio of 5 Years	35
3.14	Quick Ratio of 5 years	36
3.15	Fixed Assets to Net Worth Ratio of 2020-2024	37
3.16	Sales Ratio	38
3.17	Credit Turnover Ratio	39



*sincere appeal to the stakeholders of A Report on financial performance  
of Mankind Pharma form 2020 - 2024*

*Respected Stakeholders,*

*Hereby I am submitting a report on the financial health of the  
company based on the financial data of last 5 years (since 2022 to 2024)*

*Based on the available data a critical study is made during the  
tenure of three months. It is requested to get into the report with key  
attention. Overall the performance of the company is pretty well as it  
is known fact that nothing is perfect in the world hence it is observed  
that there are a few shortfalls in the performance of the company*

*Tools like comparative statement, common size statement, trend  
analysis, cash flow statement & ratio analysis being used to prepare  
this report. Review made on the aspects of the financial performance of  
the company. Trend analysis shows that trend being showed by  
different aspects as well the growth in different years. Ratio analysis  
helps in understanding the growth rate as well as relationship between  
different aspects of the financial statement. To ease the understanding  
in the hands of members, different charts were used to interpret the  
analysis part.*

*Hand written report is prepared to grab the special attention of  
the reader as well to reduce the printing cost of the report. It is believed  
that the report which contains the detailed analysis of the available  
data, findings, besides the suggestions which could meet the  
requirement of our members and helps in overcoming the shortfalls.*

*I express my sincere gratitude for your kind support by  
providing the data which is essential for the critical study. Unless your  
permission I would have not done my study at your premises.*

*Thank you so much.*

*With regards,*

*Rudresh patil*

## 1.1 REPORT

### 1.1.1 Meaning

A report is a structured document that presents information, findings, or results on a particular topic, event, or situation. It is designed to convey data and analysis to inform, explain, or recommend actions based on the contents. Reports are typically used in various fields such as business, science, education, and government to communicate insights and facilitate decision-making.

### 1.1.2 Definition

A report is a formal document that systematically and objectively provides information, analysis, and conclusions about a specific subject, often based on research or investigation, intended for a particular audience.

### 1.1.3 Importance of Report

- **Communication:**  
Reports convey information in a structured and organized manner, making complex topics easier to understand for a target audience.
- **Decision Making:**  
They provide data, analysis, and insights that inform decision-making processes for individuals, organizations, or governments.
- **Accountability:**  
Reports help to document actions, outcomes, and responsibilities, holding individuals or organizations accountable for their performance or decisions.
- **Documentation:**  
They serve as a record of events, research findings, or project progress, facilitating future reference or replication.
- **Problem Solving:**  
Reports often include analysis and recommendations to address specific problems or challenges, helping to identify solutions and improve processes.
- **Planning:**  
They can assist in strategic planning by providing insights into trends, opportunities, and risks, enabling organizations to make informed plans for the future.
- **Transparency:**  
Reports contribute to transparency by providing stakeholders with

access to relevant information and insights into the workings of an organization or project.

- **Evaluation:**

They enable the evaluation of projects, initiatives, or policies by assessing their effectiveness, efficiency, and impact.

Overall, reports play a crucial role in informing, guiding, and facilitating various aspects of decision-making, accountability, and communication in diverse contexts.

### 1.1.4 Features of Report

- **Title:**

Clearly states the subject and purpose of the report.

- **Introduction:**

Provides background information, objectives, and scope of the report.

- **Methodology:**

Explains how data was collected or how the report was prepared.

- **Findings/Results:**

Presents the main findings or results of the research or investigation.

- **Analysis:**

Offers interpretation and discussion of the findings, often including comparisons, trends, or implications.

- **Conclusion:**

Summarizes the main points and may offer recommendations or suggestions for further action.

- **Recommendations:**

Optional section suggesting actions based on the analysis.

- **References:**

Lists all sources cited in the report.

- **Appendices:**

Additional information, data, or supporting documents referenced in the report.

These features may vary depending on the type and purpose of the report, such as scientific, business, or academic reports.

## 1.2 FINANCIAL ANALYSIS REPORT

### 1.2.1 Meaning

A financial analysis report is a document that examines the financial health and performance of a company or organization. It typically includes an in-depth review and interpretation of financial statements, such as the balance sheet, income statement, and cash flow statement.

The report may include various financial ratios and metrics to evaluate aspects such as liquidity, profitability, solvency, and efficiency. It also often compares the company's performance to industry benchmarks or historical data to provide context and identify trends.

### 1.2.2 Definition

A financial analysis report is a comprehensive document that evaluates the financial performance, health, and position of a company or organization. It involves analyzing various financial statements, ratios, and metrics to assess factors such as profitability, liquidity, solvency, efficiency, and overall financial stability. The report typically provides insights into the company's strengths, weaknesses, opportunities, and threats, aiding stakeholders in making informed decisions related to investment, lending, strategic planning, and risk management.

### 1.2.3 Importance of Financial Analysis Report

- **Informed Decision Making:**  
They enable stakeholders such as investors, creditors, managers, and executives to make informed decisions regarding investment, lending, strategic planning, and risk management based on an accurate assessment of the company's financial position.
- **Performance Evaluation:**  
Financial analysis reports help evaluate the company's past performance and current financial status by analyzing key financial metrics and comparing them to industry benchmarks or historical data.
- **Identifying Trends and Patterns:**  
They help identify trends, patterns, and areas of improvement or

concern within the company's financial statements, allowing for proactive decision-making and corrective actions.

- **Risk Management:**

By assessing factors such as liquidity, solvency, and profitability, financial analysis reports aid in identifying and managing financial risks associated with the company's operations, investments, or market conditions.

- **Strategic Planning:**

They assist in strategic planning by highlighting opportunities for growth, potential threats, and areas where resources can be allocated more effectively to achieve the company's long-term objectives.

- **Communication:**

Financial analysis reports serve as a communication tool, facilitating dialogue and collaboration among stakeholders, including investors, creditors, management, and regulatory bodies.

Overall, financial analysis reports play a crucial role in facilitating decision-making, managing risks, and driving the success and sustainability of a company or organization.

## 1.2.4 Features of Financial Analysis Report

Financial analysis reports typically include several key features to provide a comprehensive assessment of a company's financial performance and health:

- **Executive Summary:**

A brief overview of the report's key findings, conclusions, and recommendations, designed for busy stakeholders who need a quick understanding of the main points.

- **Introduction:**

Provides background information on the company, the purpose of the analysis, and the scope of the report.

- **Financial Statements:**

Presents the company's financial statements, including the balance sheet, income statement, and cash flow statement, often for multiple periods to analyze trends over time.

- **Financial Ratios and Metrics:**

Analyzes various financial ratios and metrics to assess the company's liquidity, profitability, solvency, efficiency, and overall financial health. Common ratios include liquidity ratios, profitability ratios, leverage ratios, and efficiency ratios.

- **Trend Analysis:**

Examines trends and patterns in the company's financial performance over time, comparing key financial metrics across different periods to identify changes or areas of concern.

- **Comparative Analysis:**

Compares the company's financial performance to industry

benchmarks, competitors, or historical data to provide context and identify areas of strength or weakness.

- **Risk Assessment:**

Identifies and evaluates financial risks facing the company, such as market risks, credit risks, liquidity risks, and operational risks, and assesses their potential impact on the company's financial stability.

- **Management Discussion and Analysis (MD&A):**

Provides management's perspective on the company's financial performance, discussing significant events, trends, and factors affecting the results and future outlook.

- **Recommendations:**

Offers recommendations or suggestions for actions that the company could take to address any issues or capitalize on opportunities identified in the analysis.

- **Conclusion:**

Summarizes the key findings and insights from the analysis, highlighting the overall financial health of the company and any implications for stakeholders.

- **References and Appendices:**

Lists any sources cited in the report and includes additional supporting information, such as detailed financial calculations or supplementary data.

These features may vary depending on the specific requirements of the analysis and the intended audience of the report.

## 1.3 COMPANY PROFILE

### MANKIND PHARMA

Mankind Pharma is an Indian pharmaceutical and healthcare products company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.

As of 2023, Mankind Pharma had 25 factories and 6 R&D centers in India. The company derived 57% of its operating revenue from the Indian market, where it is reportedly the fourth largest pharmaceutical company by domestic sales. Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Man force in condoms, Prigo News in pregnancy test kits, and Unwanted-72 in emergency contraception.

#### 1.3.2 History

Mankind Pharma was incorporated in 1991 and actively started its operations in 1995, with the contributions of two brothers, Ramesh C. Juneja and Rajeev Juneja, who established the

company with a seed capital of ₹5,000,000. The company was started with 20 employees and launched in two states in the first year of its operation.

Mankind Pharma initially targeted price-sensitive drugs, with a focus on the rural market; its early products included the antibacterial drug Zenflox and the prescription antibiotic Mankind CV, which were priced at a steep discount to the existing products in the market. The company ventured into the over-the-counter segment in 2007, focusing primarily on general healthcare products.

The company acquired Magnet Labs Pvt. Ltd. to enter the anuppsychotic segment in 2007. It acquired Longifone, an appetite stimulant for children, in January 2010, which was earlier a brand of UCB.

In 2017, Mankind Pharma established Pathkind Labs, a provider of diagnostics and healthcare tests.

In 2019, Mankind became the first Indian company and second in the world to develop and launch Dydrogesterone, a drug used in high-risk pregnancies and infertility, by the brand name Dydrobon.

In 2021, Mankind acquired Panacea Biotec Pharma's domestic formulations brands in India and Nepal for ₹1,872 crore (US\$220 million). It then acquired a respiratory treatment product and an infant skincare brand from Dr. Reddy's Laboratories. It also bought a majority stake in the Ayurvedic and herbal products manufacturer, Upakarma Ayurveda.

In 2022, the company entered the agritech and pet care segments.

In April 2023, Mankind Pharma launched its initial public offering (IPO), with existing investors selling ₹4,326 crore (US\$520 million) worth of shares.

## Mankind Pharma Limited



Company type	Public
Traded as	NSE: MANKIND BSE: 543904
ISIN	INE834501028
Industry	Pharmaceutical
Founded	1991; 33 years ago
Founders	Ramesh C. Juneja Rajeev Juneja <sup>†</sup>
Headquarters	Okhla Phase III, Delhi India <sup>†</sup>
Area served	Worldwide
Key people	Ramesh Juneja (Chairman) Rajeev Juneja (MD & Vice Chairman) Sheetal Arora (CEO) Arjun Juneja (COO)
Products	Pharmaceuticals Generic drugs OTC FMCG Diagnostics
Revenue	▲ ₹10,335 crore (US\$1.2 billion) (FY24) <sup>†</sup>
Net income	▲ ₹1,542 crore (US\$230 million) (FY24) <sup>†</sup>
Number of employees	22,000+ (2023) <sup>†</sup>



## Unit 2: CONCEPTUAL FRAMEWORK

### 2.1 Title of Report

Between 2020 and 2024, Mankind Pharma experienced significant growth in its financial performance. The company's consolidated net sales for the fiscal year ending March 2024 reached INR 10,335 crores, marking an 18.1% year-on-year increase from INR 8,749 crores in FY 2023. This growth was driven by robust revenue from operations, which saw a healthy 18.5% year-on-year increase in the fourth quarter of FY 2024 alone. Throughout this period, Mankind Pharma consistently expanded its market presence and product offerings across various therapeutic areas and consumer healthcare products, reinforcing its position as one of India's leading pharmaceutical companies.

### 2.2 Purpose of The Report

Purpose of the report is to devote a better understanding different aspect of financial statement to check the financial health of Mankind pharma company. This information could be used by top management of others who need information specifically this report is required to provide information to top management of Mankind pharma company.

### 2.3 Objective of The Report

Broad range of objective sculler has set following objective to accomplish the desire result.

- The main objective of the report was to check financial health of Mankind pharma and information of the same in the top management.
- Comparative study gives clear pitcher of growth of many company. The personal study was initiated to make comparative study of income statement as well as Balance Sheet of Mankind pharma and reporting the deviation if any.
- Ratio Analysis would give detailed information about relationship between different financial aspect of financial statement of the company. Hens present report was intended to identify the relationship between various financial aspect of Mankind pharma reporting the financial health.
- Working capital vital role in any company. Therefore the management of the working capital become essential and curtail also. Hens present report was aimed to check the position of the working capital of Mankind pharma by preparing fluid flow statement and communicating the same.
- Identification of trend being followed by the company in the different financial aspect would give meager input to the management to take managerial decisions. Therefore

the present report was intended to track the trend analysis of different financial segment and communicating the same.

- Cash management had become very curtail one could not imagine an entrepreneur without a prepare Balance of cash as human body without blood cash flow statement would help enterprise to know the cash position. Hence present report was aimed to communicate the result of ups and downs of the cash position of Mankind pharma income
- The report was also intended to calculate common size statement of Mankind pharma. In order to express the segment in percentage form and communicating the same to the management

## 2.4 Collection of Data

Report is Prepared using the data which were collected by the schoolers from the secondary source's hence collected data were secondary sources.

Schoolers has visited NSE website and selected name of the company by convenient random sampling method. Then scholars have collected data from the company registered website. 5 years data has been collected and reduced the data according to the requirement uses only those data which were essential to prepare this report.

## 2.5 Tools and Techniques

The scholar used some ratio to measure the Mankind pharma financial performance and to understand the conditions position of Mankind pharma following are the ratio:

### 1. Liquidity ratio

Liquidity ratio are financial ratio that measure a company ability to repay both short- and long-term obligations

#### current ratio

- measure a company ability to pay or short-term liability with current asset.  
current ratio,  $\text{Current Asset} / \text{current Liability}$
- The cash ratio measures a company's ability to pay of short-term liability with cash of cash, Port equivalent

$$\text{cash and cash equivalent} = \frac{\text{cash and cash equivalent}}{\text{Current Liability}}$$

- The operating cash flow ratio is a measure the toppe of the number of times a company can pay off current liability with the cash generate to a given period

$$\text{Operating cash flow ratio} = \frac{\text{Operating cash flow}}{\text{Current Liability}}$$

## 2. Leverage ratio.

Leverage ratio measures the amount of capital that comes from debt in other words leverage financial ratio are used to excel veto a company debt levels common leverage ratio includes following

- The debt ratio measures the relative amount of a company asset that are provided from debt which is calculated by dividing the total liabilities by total cassette.
- The debt -to equity ratio calculates the weight of total debt and Francla liabilities against shareholder equity by dividend of total
- The interest coverage ratio how easily a company can pay its interest expenses by dividing operating income by interest expenses

## 3. Market value ratio.

This ratio is used to evaluate the share price of a company's stock common market value ratio includes

The book value per share ratio calculated the per share value of a company based on the equity available to shareholder This is calculated by dividing the amount by total common share outstanding which we can get after deducting the performed equity from shareholder equity.

The dividend yield ratio measures the amount of dividend attributed to shareholders reliable to market value per share we can find out this ratio by dividing dividend per share by share price

## 4. Profitability ratio

The ratio measures a company to generate income relative to revenue balance sheet asset operating cost and cost of equity common profitability financial ratio includes is the following

The gross margin ratio companies the gross profit of a company to its net sales to show how much profit a company to its net sales to show how much profit a company make goods sold By net sales after paying its, cost of dividing the gross profit we can calculate this ratio

The operating margin ratio also known as return on sales ratio compares the operating income of a company to its net sales to determine operating efficiency. A company's formula is operating income divided by net sales.

## 2.6 Scope of the Report

- The present report was prepared based on the data of 5 years therefore it would give enough information to the management to take managerial decisions.
- In the preparation of present report following tools had been used by the sculler is knowledge they are **Current ratio, Quick ratio, Sales ratio, Operating profit ratio, Net profit ratio, Debtor turnover ratio**
- Present report certain various table chart and diagram which would enable reader to get more deeper since of knowledge on the report.
- The source of data was form register website mankind pharma.in and of was prepared by expert qualified accountant here there is no space for the mistake in data and therefor of report.
- This report is useful to various stakeholders of the company to take managerial decisions
- Most important thing is this report was written by scholars using simple and understandable language and understood accordingly

## 2.7 Desire output and outcomes.

- Determination of financial health of Mankind pharma to empower management to take managerial decision
- Identification of Devotion of in the financial performance Mankind pharma emporia the management to take corresponding
- In general improving the management of Mankind pharma via suggestions.

A financial report typically follows a structured format to present information clearly and systematically. The structure may vary slightly depending on the organization, regulatory requirements, and the purpose of the report, but a comprehensive financial report generally includes the following sections:

## 2.8 Structure of Report

For the convenience of the reader entire content of the report is made brief & presented in the form of structure of the report.

Structure of the report enables the reader to glance on the entire matter of the report within a short period. It is just like an express way to get to the detailed view.

hence the scholars had the unit wise information briefly.

### • Unit 1 – Introduction

First unit enable the reader to understand the concept of financial analysis reporting and it had concerned other aspect of the financial analysis reporting. It's objectives, feature, scope, process, limitations, essentials of good report, essential quality of good report, recent trends, studied & collected essential details of the company from the registered website [www.mankindpharma.com](http://www.mankindpharma.com) of Mankind pharma limited and is made available to the reader.

### • Unit 2 – Conceptual Framework

Second unit reveals the attempt of the scholar regarding the elucidation of objectives for the preparation of present report. There was the objective led by the scholar had extended his or her attempts to describe the scope of the report, information used to prepare the report, limiting factors of report & briefly explored the entire content of the report using structure of the report. Second unit enables the reader to understand the conceptual framework carried out by scholars with respect of their particular report.

### • Unit 3 – Data Analysis and Interpretation

Third unit reveals the data analysis part of the report, main part of the report where scholar had reported to give clean picture of data analysis using table as well as charts & diagrams. This gives deep sense of knowledge to the reader as well as the management. In fact this unit ensure that management can take good managerial decision.

### • Unit 4 – Findings, Suggestions and Conclusion

This unit contains the result part of the report. In this unit scholar had identified findings based on the interpreted result of 3<sup>rd</sup> unit. Scholars had specified various suggestions & concluded the entire report very briefly.

Based on the detailed study, scholars had drafted financial analysis report of Mankind Pharma Ltd.

## 2.9 Limitations of Report

- Financial reports are primarily historical documents. They provide information about past performance and financial position, which may not be indicative of future performance. This limitation means that stakeholders must consider other sources and analyses to predict future trends.
- Financial reports focus on quantitative data and financial metrics, often neglecting qualitative factors such as employee morale, customer satisfaction, and market conditions. These qualitative factors can significantly impact an organization's future performance but are not captured in standard financial statements.
- While financial reports must comply with accounting standards (GAAP, IFRS), these standards can vary between countries and industries. This variability can make it difficult to compare financial reports across different organizations or geographical locations. Additionally, adherence to these standards can sometimes limit the flexibility of how financial information is presented.
- Financial reports often rely on estimates and judgments for certain items, such as depreciation, bad debt provisions, and inventory valuations. These estimates can be subjective and may vary significantly between different organizations or periods, potentially affecting the comparability and accuracy of the financial statements.
- Financial statements are typically prepared using historical cost accounting, which does not account for the effects of inflation. Over time, inflation can distort the real value of assets, liabilities, and equity, making it challenging to assess an organization's true financial position and performance.

## Unit 3: ANALYSIS AND INTERPRETATION

### 3.1 Comparative Statement

#### 3.1.1 Meaning

Comparative financial statement displays the financial performance of 2 or more period such as consecutive quarter or years. These statements typically include income statement, balance sheet and cash flow statement by presenting the financial data in the side-by-side manner stakeholders can easily identify the trend growth pattern and potential issues.

#### 3.1.2 Objective of comparative statement

- **Trend Analysis:** To identify trends in revenue, expenses, profits, and other key financial metrics over time.
- **Performance Evaluation:** To assess the company's performance by comparing current results with previous periods.
- **Decision Making:** To aid management and stakeholders in making informed decisions based on historical performance.
- **Benchmarking:** To compare the company's performance against industry standards or competitors.
- **Identifying Variations:** To pinpoint significant changes and variations in financial data, which can indicate areas of concern or success.

Table 3.1 Comparative Balance 2020-2021

**Comparative Balance sheet of  
MANKIND PHARMA 2020-2021**

	2020	2021	Change	Percentage
<b>EQUITIES AND LIABILITIES</b>				
<b>SHAREHOLDER'S FUNDS</b>				
Equity Share Capital	40.00	40.00	0	0.00
<b>TOTAL SHARE CAPITAL</b>	<b>40.00</b>	<b>40.00</b>	<b>0</b>	<b>0.00</b>
Reserves and Surplus	3611.39	4694.21	1082.82	29.98
<b>TOTAL RESERVES AND SURPLUS</b>	<b>3611.39</b>	<b>4694.21</b>	<b>1082.82</b>	<b>29.98</b>
<b>TOTAL SHAREHOLDERS FUNDS</b>	<b>3651.45</b>	<b>4734.27</b>	<b>1082.82</b>	<b>29.65</b>
<b>NON-CURRENT LIABILITIES</b>				
Long Term Borrowings	0	0	0	0.00
Deferred Tax Liabilities (Net)	0	0	0	0.00
Other Long Term Liabilities	37.47	30.77	-6.7	-38.35
Long Term Provisions	46.41	56.39	9.98	21.50
<b>TOTAL NON-CURRENT LIABILITIES</b>	<b>63.89</b>	<b>67.15</b>	<b>3.26</b>	<b>5.10</b>
<b>CURRENT LIABILITIES</b>				
Short Term Borrowings	0	85	85	85.00
Trade Payables	487.23	591.08	106.85	0.00
Other Current Liabilities	150.31	200.04	43.73	27.45
Short Term Provisions	109.23	186.79	17.56	10.38
<b>TOTAL CURRENT LIABILITIES</b>	<b>815.77</b>	<b>1078.61</b>	<b>268.14</b>	<b>32.25</b>
<b>TOTAL CAPITAL AND LIABILITIES</b>	<b>4531.11</b>	<b>5880.33</b>	<b>1349.22</b>	<b>29.78</b>
<b>ASSETS</b>				
<b>NON-CURRENT ASSETS</b>				
Tangible Assets	917.35	965.38	48.03	5.24
Intangible Assets	21.9	10.58	-5.33	-24.29
Capital Work-In-Progress	143.03	165.51	21.58	14.99
Other Assets	5.51	5.46	-0.05	-0.91



<b>FIXED ASSETS</b>	1092.39	1152.98	60.59	5.55
Non-Current Investments	1389.51	1500.86	111.35	8.01
Deferred Tax Assets (Net)	21.05	13.64	-8.01	-38.05
Long Term Loans And Advances	0	0	0	0.00
Other Non-Current Assets	781.86	121.47	-660.39	-84.52
<b>TOTAL NON-CURRENT ASSETS</b>	<b>2582.5</b>	<b>2790.35</b>	<b>207.85</b>	<b>8.05</b>
<b>CURRENT ASSETS</b>			0	0.00
Current Investments	394.16	896.03	501.87	127.33
Inventories	531.48	826.91	295.43	55.60
Trade Receivables	418.62	369.17	-49.45	-11.81
Cash And Cash Equivalents	197.85	476.95	279	140.94
Short Term Loans And Advances	211.88	227.17	15.29	7.22
Other Current Assets	192.51	293.75	101.24	52.59
<b>TOTAL CURRENT ASSETS</b>	<b>1948.6</b>	<b>3089.98</b>	<b>1141.38</b>	<b>58.57</b>
<b>TOTAL ASSETS</b>	<b>4531.11</b>	<b>5880.33</b>	<b>1349.22</b>	<b>29.78</b>

### Interpretation

The comparative balance sheet of Mankind Pharma for 2021-2022 shows significant growth across various financial metrics. Shareholder's funds increased by 29.65%, driven by a substantial rise in reserves and surplus. Non-current liabilities saw a minor increase of 5.10%, while current liabilities surged by 32.26%, largely due to new short-term borrowings and higher trade payables. On the assets side, non-current assets grew by 8.05%, with notable increases in tangible assets and non-current investments. Current assets experienced a remarkable increase of 58.57%, highlighted by significant growth in current investments, inventories, and cash and cash equivalents. Overall, total assets and total capital and liabilities both grew by 29.78%, indicating a strong financial performance and expansion of Mankind Pharma during this period.

Table 3.2 Comparative Balance 2021-2022

### Comparitive Balance sheet of MANKIND PHARMA 2021-2022

	2021	2022	Change	Percentage
<b>EQUITIES AND LIABILITIES</b>				
<b>SHAREHOLDER'S FUNDS</b>				
Equity Share Capital	40.00	40.00	0	0.00

TOTAL SHARE CAPITAL	40.06	40.06	0	0.00
Reserves and Surplus	4004.21	6028.72	1334.51	28.43
<b>TOTAL RESERVES AND SURPLUS</b>	<b>4004.21</b>	<b>6028.72</b>	<b>1334.51</b>	<b>28.43</b>
<b>TOTAL SHAREHOLDERS FUNDS</b>	<b>4004.21</b>	<b>6008.77</b>	<b>1334.51</b>	<b>28.19</b>
<b>NON-CURRENT LIABILITIES</b>				
Long Term Borrowings	0	2.44	0	0.00
Deferred Tax Liabilities (Net)	0	35.71	35.71	0.00
Other Long Term Liabilities	10.77	15.23	4.46	41.41
Long Term Provisions	56.39	62.65	6.3	11.17
<b>TOTAL NON-CURRENT LIABILITIES</b>	<b>67.15</b>	<b>116.06</b>	<b>48.91</b>	<b>72.84</b>
<b>CURRENT LIABILITIES</b>				
Short Term Borrowings	35	685.45	550.45	621.53
Trade Payables	594.08	974.88	330.8	0.00
Other Current Liabilities	203.04	383.04	180	88.63
Short Term Provisions	186.79	234.63	47.84	25.61
<b>TOTAL CURRENT LIABILITIES</b>	<b>1078.93</b>	<b>2228.01</b>	<b>1149.1</b>	<b>108.51</b>
<b>TOTAL CAPITAL AND LIABILITIES</b>	<b>5880.33</b>	<b>8412.85</b>	<b>2582.52</b>	<b>43.07</b>
<b>ASSETS</b>				
<b>NON-CURRENT ASSETS</b>			0	0.00
Tangible Assets	905.38	1039.87	74.49	7.72
Intangible Assets	15.58	1841.27	1824.69	11005.37
Capital Work-in-Progress	165.51	355.28	189.77	134.66
Other Assets	5.45	5.38	-0.08	-1.47
<b>FIXED ASSETS</b>	<b>1452.98</b>	<b>3273.09</b>	<b>2120.1</b>	<b>183.88</b>
Non-Current Investments	1500.86	1760.07	259.81	17.31
Deferred Tax Assets (Net)	13.04	0	-13.04	-100.00
Long Term Loans And Advances	0	0	0	0.00
Other Non-Current Assets	119.47	122.32	-1.15	-0.93
<b>TOTAL NON-CURRENT ASSETS</b>	<b>2790.35</b>	<b>5356.07</b>	<b>2365.72</b>	<b>84.78</b>
<b>CURRENT ASSETS</b>			0	0.00
Current Investments	896.03	387.77	-508.26	-56.72
Inventories	826.91	1225.79	398.88	48.24
Trade Receivables	369.17	517.29	148.12	40.17
Cash And Cash Equivalents	476.95	73.18	-403.76	-84.65
Short Term Loans And Advances	227.17	145.75	-81.42	-35.34

Other Current Assets	293.76	976.58	613.23	208.76
<b>TOTAL CURRENT ASSETS</b>	<b>3089.98</b>	<b>3256.78</b>	<b>166.8</b>	<b>5.40</b>
<b>TOTAL ASSETS</b>	<b>5880.33</b>	<b>8412.85</b>	<b>2532.52</b>	<b>43.07</b>

## Interpretation

The comparative balance sheet of Mankind Pharma for 2021-2022 reveals substantial growth and significant financial changes. Shareholder's funds rose by 28.19%, driven by a 28.43% increase in reserves and surplus. Non-current liabilities increased dramatically by 71.84%, mainly due to new long-term borrowings and deferred tax liabilities. Current liabilities more than doubled, increasing by 106.51%, largely due to a substantial rise in short-term borrowings and trade payables. On the assets side, non-current assets surged by 84.78%, with a notable increase in intangible assets and capital work-in-progress. Tangible assets also grew by 7.72%. However, current assets saw modest growth of 5.40%, with significant changes within categories: a large increase in inventories and other current assets was offset by a sharp decline in cash and cash equivalents and current investments. Overall, total assets and total capital and liabilities grew by 43.07%, indicating strong expansion and significant investment in long-term growth.

**Table 3.3 Comparative Balance 2022-2023**

### Comparitive Balance sheet of MANKIND PHARMA 2022-2023

	2022	2023	Change	Percentage
<b>EQUITIES AND LIABILITIES</b>				
<b>SHAREHOLDER'S FUNDS</b>				
Equity Share Capital	40.06	40.06	0	0.00
<b>TOTAL SHARE CAPITAL</b>	<b>40.06</b>	<b>40.06</b>	<b>0</b>	<b>0.00</b>
Reserves and Surplus	6028.72	7743.85	1715.13	28.45
<b>TOTAL RESERVES AND SURPLUS</b>	<b>6028.72</b>	<b>7743.85</b>	<b>1715.13</b>	<b>28.45</b>
<b>TOTAL SHAREHOLDERS FUNDS</b>	<b>6068.77</b>	<b>7783.91</b>	<b>1715.14</b>	<b>28.26</b>
<b>NON-CURRENT LIABILITIES</b>				
Long Term Borrowings	2.44	0	-2.44	-0.00
Deferred Tax Liabilities (Net)	35.71	35.85	0.14	0.00
Other Long Term Liabilities	19.23	23.4	4.17	53.64

Long Term Provisions	62.09	88.27	26.18	41.75
<b>TOTAL NON-CURRENT LIABILITIES</b>	<b>116.06</b>	<b>168.12</b>	<b>52.06</b>	<b>44.86</b>
<b>CURRENT LIABILITIES</b>				
Short Term Borrowings	685.45	0	-685.45	-100.00
Trade Payables	524.88	801.96	-277.02	0.00
Other Current Liabilities	383.04	322.53	-60.51	-15.80
Short Term Provisions	234.63	264.59	99.96	25.56
<b>TOTAL CURRENT LIABILITIES</b>	<b>2228.01</b>	<b>1419.09</b>	<b>-808.92</b>	<b>-36.31</b>
<b>TOTAL CAPITAL AND LIABILITIES</b>	<b>8412.86</b>	<b>9371.12</b>	<b>958.27</b>	<b>11.39</b>
<b>ASSETS</b>				
<b>NON-CURRENT ASSETS</b>			0	0.00
Tangible Assets	1039.87	1435.81	395.94	38.08
Intangible Assets	1841.27	1701.08	-140.19	-7.61
Capital Work-In-Progress	355.28	437.83	82.55	23.24
Other Assets	5.38	5.32	-0.06	-1.12
<b>FIXED ASSETS</b>	<b>3223.08</b>	<b>3637</b>	<b>363.92</b>	<b>11.12</b>
Non-Current Investments	1760.67	2040.76	280.09	15.91
Deferred Tax Assets (Net)	0	0	0	0.00
Long Term Loans And Advances	0	0	0	0.00
Other Non-Current Assets	122.32	176.45	54.12	44.25
<b>TOTAL NON-CURRENT ASSETS</b>	<b>5156.07</b>	<b>5854.21</b>	<b>698.14</b>	<b>13.54</b>
<b>CURRENT ASSETS</b>			0	0.00
Current Investments	367.77	1061.47	673.7	173.74
Inventories	1225.79	1032.22	-193.57	-15.79
Trade Receivables	517.29	492.64	-24.65	-4.77
Cash And Cash Equivalents	73.19	155.15	81.96	111.98
Short Term Loans And Advances	145.75	98.34	-47.41	-32.53
Other Current Assets	906.98	677.09	-229.89	-25.35
<b>TOTAL CURRENT ASSETS</b>	<b>3256.78</b>	<b>3516.91</b>	<b>260.13</b>	<b>7.99</b>
<b>TOTAL ASSETS</b>	<b>8412.85</b>	<b>9371.12</b>	<b>958.27</b>	<b>11.39</b>

## Interpretation

The comparative balance sheet of Mankind Pharma for 2022-2023 indicates continued financial growth and restructuring. Shareholder's funds increased by 28.26%, driven by a significant rise in reserves and surplus. Non-current liabilities grew by 44.66%, largely due to

increased deferred tax liabilities and other long-term liabilities. Conversely, current liabilities decreased by 36.31%, primarily due to the elimination of short-term borrowings and reduced trade payables. On the assets side, non-current assets rose by 13.54%, with tangible assets growing by 38.08% and significant investments in capital work-in-progress and non-current investments. However, intangible assets slightly declined by 7.61%. Current assets saw a modest increase of 7.99%, highlighted by a substantial rise in current investments and cash and cash equivalents, despite a reduction in inventories and other current assets. Overall, total assets and total capital and liabilities increased by 11.39%, reflecting solid financial performance and strategic investment in long-term growth.

**Table 3.4 Comparative Balance 2022-2024**

**Comparative Balance sheet of  
MANKIND PHARMA 2023-2024**

	2023	2024	Change	Percentage
<b>EQUITIES AND LIABILITIES</b>				
<b>SHAREHOLDER'S FUNDS</b>				
Equity Share Capital	40.06	40.06	0	0.00
<b>TOTAL SHARE CAPITAL</b>	<b>40.06</b>	<b>40.06</b>	<b>0</b>	<b>0.00</b>
Reserves and Surplus	7743.85	9583.75	1839.9	23.76
<b>TOTAL RESERVES AND SURPLUS</b>	<b>7743.85</b>	<b>9583.75</b>	<b>1839.9</b>	<b>23.76</b>
<b>TOTAL SHAREHOLDERS FUNDS</b>	<b>7783.91</b>	<b>9623.81</b>	<b>1839.9</b>	<b>23.64</b>
<b>NON-CURRENT LIABILITIES</b>				
Long Term Borrowings	0	5.95	0	0.00
Deferred Tax Liabilities (Net)	55.85	71.59	15.74	0.00
Other Long Term Liabilities	23.4	11.21	-12.19	-52.06
Long Term Provisions	89.97	111.79	21.92	25.79
<b>TOTAL NON-CURRENT LIABILITIES</b>	<b>169.12</b>	<b>200.54</b>	<b>31.42</b>	<b>19.28</b>
<b>CURRENT LIABILITIES</b>				
Short Term Borrowings	0	2.67	2.67	6011/05
Trade Payables	801.96	848.52	47.56	0.00
Other Current Liabilities	322.53	368.12	45.59	14.14
Short Term Provisions	294.59	373.11	78.52	26.65
<b>TOTAL CURRENT LIABILITIES</b>	<b>1419.08</b>	<b>1593.36</b>	<b>174.27</b>	<b>12.28</b>

**TOTAL CAPITAL AND LIABILITIES**

<b>ASSETS</b>	<b>9371.12</b>	<b>11417.71</b>	<b>2046.59</b>	<b>21.84</b>
<b>NON-CURRENT ASSETS</b>				
Tangible Assets			0	0.00
Intangible Assets	1435.81	3521.92	2156.11	150.17
Capital Work-In-Progress	1701.08	0	-1701.08	-100.00
Other Assets	437.83	0	-437.83	-100.00
<b>FIXED ASSETS</b>	<b>5.32</b>	<b>0</b>	<b>-5.32</b>	<b>-100.00</b>
Non-Current Investments	3837	3521.92	-45.98	-1.24
Deferred Tax Assets (Net)	2040.76	2150.62	149.85	7.34
Long Term Loans And Advances	0	0	0	0.00
Other Non-Current Assets	0	8.74	8.74	0.00
<b>TOTAL NON-CURRENT ASSETS</b>	<b>5854.21</b>	<b>5858.79</b>	<b>4.58</b>	<b>0.08</b>
<b>CURRENT ASSETS</b>			0	0.00
Current Investments	1061.47	2239.51	1178.04	110.98
Inventories	1032.22	1075.59	43.37	4.20
Trade Receivables	482.64	749.47	256.83	52.13
Cash And Cash Equivalents	155.15	761.01	605.86	390.50
Short Term Loans And Advances	58.34	39.92	-58.42	-59.41
Other Current Assets	677.09	693.42	16.33	2.41
<b>TOTAL CURRENT ASSETS</b>	<b>3516.91</b>	<b>5558.92</b>	<b>2042.01</b>	<b>58.08</b>
<b>TOTAL ASSETS</b>	<b>9371.12</b>	<b>11417.71</b>	<b>2046.59</b>	<b>21.84</b>

**Interpretation**

The comparative balance sheet of Mankind Pharma for 2023-2024 highlights notable growth and strategic shifts in the company's financial structure. Shareholder's funds increased by 23.64%, driven by a substantial rise in reserves and surplus. Non-current liabilities grew by 19.28%, with notable increases in long-term borrowings and provisions, despite a significant reduction in other long-term liabilities. Current liabilities rose by 12.28%, influenced by the reintroduction of short-term borrowings and increased trade payables and provisions. On the assets side, tangible assets surged by 150.17%, while intangible assets, capital work-in-progress, and other assets were completely written off. Non-current assets remained stable overall, with a slight increase of 0.08%. Current assets experienced significant growth of 58.06%, led by substantial increases in current investments, cash and cash equivalents, and trade receivables. Overall, total assets and total capital and liabilities increased by 21.84%, indicating robust financial health and a focus on enhancing liquidity and tangible asset base.

## 3.2 Trend Analysis

### 3.2.1 Meaning

Trend analysis is a method used in financial analysis to examine and predict the future movements of financial data by analyzing historical data. It involves identifying patterns or trends in financial performance over multiple periods. This analysis helps stakeholders understand the direction in which the business is moving and make informed decisions.

### 3.2.2 Objectives


The primary objectives of trend analysis are:

- **Identify Patterns:** To detect patterns in financial performance over time, such as consistent growth or decline.
- **Forecast Future Performance:** To predict future financial outcomes based on historical trends.
- **Evaluate Performance:** To assess the company's performance by comparing current data with past data, determining whether the business is improving, stagnating, or declining.
- **Budgeting and Planning:** To assist in financial planning and budgeting by providing insights into future revenue, expenses, and other key financial metrics.
- **Identify Anomalies:** To spot irregularities or unusual deviations from expected trends, which may indicate potential issues or areas requiring attention.

Table 3.5 Trend Analysis

year	Sales		Stock		Profit Before Tax	
	Amount	Percentage	Amount	Percentage	Amount	Percentage
2020	4730.15	100%	533.48	100	1264.92	100
2021	5485.16	115.98	826.91	155.00	1440.21	113.85
2022	7240.86	153.08	1275.79	229.77	1797.54	142.11
2023	8120.57	171.68	1032.22	193.49	1567.84	123.55
2024	9264.81	195.87	1075.59	201.62	2259.57	178.63

Graph 3.1 Sales Trend Analysis




Interpretation



From 2020 to 2024, Mankind Pharma experienced a significant growth in sales, with an increase from ₹4,730.15 million to ₹9,264.81 billion. This represents a growth of 53.87% over five years. The annual increments show a steady upward trend, with sales increasing by approximately 15-20% each year. The largest increase occurred between 2021 and 2022, where sales jumped by 37.08%. This consistent growth indicates a strong market presence and successful business strategies in capturing a large market share and driving revenue.


**Graph 3.2 Stock Trend Analysis**



**Interpretation**

The stock levels of Mankind Pharma also saw notable changes, increasing from ₹533.48 million in 2020 to ₹1,075.59 million in 2024. This represents a growth of 101.62% over the five-year period. The stock levels peaked in 2022 at ₹1,225.79 million, reflecting the company's inventory buildup to meet increasing sales demands. However, a slight dip in stock levels occurred in 2023, possibly indicating improved inventory management or a strategic reduction in stock holdings. Overall, the growth in stock levels aligns with the increasing sales, ensuring company maintains adequate inventory to support its expanding operations.

**Graph 3.3 Profit Before Tax (PBT)**



### **Interpretation**

Profit Before Tax (PBT) for Mankind Pharma shows a robust upward trend from 2020 to 2024, increasing from ₹1,264.92 million to ₹2,259.57 million. This marks an increase of 78.63% over the five years. The profit margins exhibit strong growth, particularly between 2022 and 2024, where PBT rose significantly by 42.11% and 78.63%, respectively. The dip in 2023, with a lower growth rate of 23.55%, suggests some challenges that impacted profitability temporarily. Nonetheless, the overall trend reflects the company's ability to enhance profitability through effective cost management and scaling operations efficiently.

### **Overall interpretation of trend analysis**

The trend analysis of Mankind Pharma from 2020 to 2024 reveals a consistent and robust growth trajectory across key financial metrics. Sales have nearly doubled, increasing from ₹4730.15 crore in 2020 to ₹9264.81 crore in 2024, reflecting a substantial growth rate of 55.87%. Stock levels have also risen significantly, from ₹533.48 crore in 2020 to ₹1075.59 crore in 2024, a 101.62% increase, suggesting a strategic approach to inventory management and capacity expansion. Profit before tax shows a notable upward trend, growing from ₹1264.92 crore in 2020 to ₹2259.57 crore in 2024, an increase of 78.53%, indicating enhanced operational efficiency and profitability. This overall growth highlights the company's strong market presence, effective cost management, and successful strategic initiatives.

### 3.3 Ratio Analysis

#### 3.3.1 Meaning

Ratio analysis is a quantitative method used to gain insights into a quantitative performance by comparing various financial metric if involves key financial ratio from financial data from percent in financial statement like the financial balance sheet, income statement and cash flow statement.

#### 3.3.2 Objectives

The primary objectives of ratio analysis are:

- **Performance Evaluation:** To assess the overall financial performance and health of a company.
- **Trend Analysis:** To identify trends and changes in financial performance over different periods.
- **Comparative Analysis:** To compare a company's financial metrics against industry benchmarks or competitors.
- **Decision Making:** To aid management and stakeholders in making informed business decisions.
- **Financial Planning:** To assist in financial planning and forecasting by highlighting strengths and weaknesses.
- **Investment Assessment:** To provide insights for investors to evaluate the attractiveness and risks of investing in a company.

Data for 2020-2024

(All amounts in €)

Sales

2024	2023	2022	2021	2020
654.51	8120.57	7240.85	5480.16	4730.15

COGS: opening stock + (purchase) - closing stock

2024	2023	2022	2021	2020
2077.03	2183.3	3185.49	2329.85	1669.4

Fixed Assets:

2024	2023	2022	2021	2020
2591.92	3697	3273.08	1152.95	1092.35

Capital:

2024	2023	2022	2021	2020
40.06	40.06	40.06	40.06	40.06

Tangible fixed Assets

2024	2023	2022	2021	2020
5591.52	1435.81	1039.87	965.38	917.35

Debtors

2024	2023	2022	2021	2020


2024 492.64 517.29 308.17 418.62

### 1. Current Ratio

$$\text{Current Ratio} = \frac{\text{Current Assets}}{\text{Current Liabilities}}$$

	2024	2023	2022	2021	2020
Current Assets	9264.81	8120.57	7240.88	5486.16	4730.15
Current Liabilities	1593.36	1419.09	2228.01	1078.91	815.77
Total	5.81	5.72	3.25	5.06	5.80

Graph 3.4 Current Ratio of 5 Years



### Interpretation:

The financial data provided shows the current assets and current liabilities for the years 2020 to 2024. Over this period, current assets have consistently increased from 4730.15 in 2020 to 9264.81 in 2024. On the other hand, current liabilities have fluctuated, with a notable increase from 815.77 in 2020 to a peak of 2228.01 in 2022 before decreasing to 1593.36 in 2024. The "Total" values, which likely represent the current ratio (current assets divided by current liabilities), indicate the company's liquidity position. A higher current ratio suggests better liquidity. The current ratio remained relatively strong, with slight variations, from 5.81 in 2020 to 5.72 in 2021, dropping significantly to 3.25 in 2022, and then rising again to 5.72 in


2023 and 5.81 in 2024. This trend suggests that the company generally maintained a good liquidity position, although there was a dip in 2022.

### 2. Quick Ratio

$$\text{Current Ratio} = \frac{\text{Current Assets} - \text{Stock}}{\text{Current Liabilities}}$$

	2024	2023	2022	2021	2020
Current Assets	2857.99	2724.94	3591.04	4352.85	5129.17
Stock	9.76	6.54	7.93	9.61	10.97
Current Liabilities	1786.29	1537.78	1764.63	2391.37	2631.43
Total	5.81	5.72	3.25	5.08	5.8

Graph 3.5 Quick Ratio of 5 years



### Interpretation


The financial data shows the current assets, stock values, and current liabilities for the years 2020 to 2024. Current assets have shown a general downward trend from 5129.17 in 2020 to 2857.99 in 2024. Stock values have also decreased from 10.97 in 2020 to 9.76 in 2024, with some fluctuations in between. Current liabilities have decreased from 2631.43 in 2020 to 1786.29 in 2024, indicating an improvement in the company's debt position. The "Total" values, which likely represent a financial ratio such as the current ratio, show a relatively stable trend with a significant drop in 2022 (3.25) but remaining around 5.72 to 5.81 in the other years, indicating that the company maintained a strong liquidity position overall.

### 3. Fixed Assets to Net worth Ratio

$$\text{Sales Ratio} = 100 \times \frac{\text{Fixed assets}}{\text{Shareholder fund}}$$

	2024	2023	2022	2021	2020
Fixed Assets	3591.92	3637	3279.68	1152.98	1072.70
Shareholders fund	9623.81	7783.91	6058.77	4734.27	3651.45
Total	37.32326	46.72459	53.9316932	24.33391	29.91661

Graph 3.6 Fixed Assets to Net Worth Ratio of 2020-2024



#### Interpretation


The sales-to-total assets ratios from 2020 to 2024 exhibit significant variability but generally reflect an improving efficiency in utilizing assets to generate sales. Starting at 70.01% in 2020, the ratio drops sharply to 24.73% in 2021, likely indicating a period of lower sales performance or higher asset base. However, the ratio rebounds to 48.97% in 2022 and continues to increase to 69.58% in 2023, finally stabilizing at 70.11% in 2024. This upward trend from 2021 onwards suggests a recovery and enhanced effectiveness in asset utilization, culminating in a consistent and robust performance by 2024. The fluctuations also highlight the company's ability to adapt and optimize its asset base over time to achieve better sales outcomes.

#### 4. Sales Ratio

$$\text{Sales Ratio} = 100 \times \frac{\text{Sales}}{\text{Total Assets}}$$

	2024	2023	2022	2021	2020
Sales	9264.81	8120.57	7140.86	5486.16	4730.15
Dr	749.47	482.64	537.29	369.17	418.62
Total	12.361816	16.48378	13.99768	14.8608	11.29939

Graph 3.7 Sales Ratio



#### Interpretation

The data outlines the sales, Dr (possibly debtors or direct costs), and a "Total" metric from 2020 to 2024. Sales have shown a strong upward trend, increasing from 4730.15 in 2020 to 9264.81 in 2024, indicating significant revenue growth. The Dr values also increased, from 418.62 in 2020 to 749.47 in 2024, which could imply higher direct costs or an increase in debtors as sales grew. The "Total" values, which likely represent a financial ratio or efficiency metric, fluctuated over the years. It peaked at 16.48378 in 2021 and had the lowest value at 11.29939 in 2020, reflecting varying efficiency or profitability across the years. Despite fluctuations, the overall trend suggests improvement and growth in the company's financial




performance highlight the company's dynamic approach in managing receivables and optimizing its cash flow relative to sales.

### 5. Creditors Turnover Ratio

	Creditor turnover ratio = $\frac{\text{Sales}}{\text{Average creditor}}$				
	2020	2021	2022	2023	2024
Sales	2275.18	782.96	1879.1	3540.7	4270.18
Average Creditors	181.335	174.925	429.455	765.375	924.78
Total	12.55	4.48	4.38	4.63	4.62

Graph 3.8 Creditor Turnover Ratio



#### Interpretation

The sales-to-average creditors ratios from 2020 to 2024 indicate changes in the company's ability to manage its obligations to creditors in relation to its sales. Starting at a high of 12.55 in 2020, the ratio drops sharply to 4.48 in 2021 and remains relatively stable around this lower range in the subsequent years: 4.38 in 2022, 4.63 in 2023, and 4.62 in 2024. The initial high ratio in 2020 suggests a strong ability to generate sales relative to the average amount owed to creditors. However, the significant drop in 2021 and the stability around the lower ratio in the following years indicate either an increase in average creditors or a more cautious approach to managing payables. The relatively stable ratios from 2021 onwards reflect a consistent balance between sales and creditor obligations, implying that the

company has adjusted to a more sustainable level of leveraging its credit to support sales growth.

### Overall Ratio Analysis Interpretation

The financial data from 2020 to 2024 indicates a positive growth trend for the company. Sales have nearly doubled from 4730.15 in 2020 to 9264.81 in 2024, reflecting strong revenue growth. Despite some fluctuations, the Dr values have increased overall, suggesting higher direct costs or a rise in debtors. The "Total" metric, which likely represents a financial ratio, varied over the years, peaking at 16.48378 in 2021 and reaching its lowest at 11.29939 in 2020. This variability indicates changes in efficiency or profitability, but the general trend shows improvement and growth in the company's financial health.

## Unit 4: SUMMERY OF THE REPORT

## 4.1 Key Findings

### 1. Improving Liquidity:

The current ratio increased from 1.59 in 2020 to 1.95 in 2024, indicating enhanced liquidity and an improved ability to meet short-term obligations.

### 2. Variability in Efficiency:

The sales-to-total assets ratio showed significant fluctuations, with a sharp drop in 2021 followed by a recovery and stabilization by 2024.

### 3. Improved Asset Utilization:

The ratio increased from 24.73% in 2021 to 70.11% in 2024, reflecting a recovery and enhanced efficiency in utilizing assets to generate sales.

### 4. Consistent Growth:

Mankind Pharma's sales have increased every year, showcasing robust growth from ₹4,730.15 million in 2020 to ₹9,264.81 million in 2024.

### 5. Rising Inventory Levels:

Stock levels have generally increased from ₹533.48 million in 2020 to ₹1,075.59 million in 2024, reflecting the company's efforts to meet growing sales demands.

### 6. Healthy Profit Growth:

Profit before tax increased from ₹1,364.92 million in 2020 to ₹2,259.57 million in 2024, indicating a strong financial performance.

### 7. Robust Current Ratio:

The current ratio, representing the company's ability to cover its short-term liabilities with its short-term assets, has remained strong, fluctuating slightly but indicating overall good liquidity.

## 4.2 Suggestions

### 1. Digital Marketing:

Invest in advanced digital marketing strategies to reach a broader audience and enhance brand visibility.

### 2. Inventory Optimization:

Utilize advanced inventory management systems to optimize stock levels, reducing holding costs while ensuring availability.

### **3. Cost Control:**

Continuously monitor and control operational costs.

### **4. Increase Current Assets:**

Focus on increasing current assets through better cash management, improving inventory turnover, and enhancing accounts receivable collections.

### **5. Reduce Current Liabilities:**

Negotiate better payment terms with suppliers to extend payment periods, thereby reducing current liabilities.

## **4.3 Conclusions**

### **1. Improving Liquidity:**

The current ratios from 2020 to 2024 show a positive trend, indicating enhanced liquidity and the ability to meet short-term obligations.

### **2. Creditor Management:**

The sales-to-average creditors ratios show a significant drop and stabilization, suggesting a more sustainable approach to managing obligations to creditors.

### **3. Profit Before Tax:**

- Profit before tax showed steady growth, with a notable increase from 2023 to 2024.
- Effective cost management and operational efficiency are key contributors to improved profitability.

### **4. Fluctuating Efficiency:**

The "Total" metric, likely representing a financial ratio, showed variability, indicating inconsistencies in operational efficiency and profitability.

### **5. Cost Management:**

Monitor and control direct costs to ensure they do not rise disproportionately with sales.

Negotiate better terms with suppliers and optimize inventory management.

## **REFERENCES AND BIBLIOGRAPHY**

## References

Google: Mankind Pharma company information . Retrieved from Google and Wikipedia

Moneycontrol Financial Charts: Balance Sheet, Profit and Loss Account. Retrieved from Moneycontrol.com

## Bibliography

Google. (n.d) Mankind Pharma company information . Retrieved from Google and Wikipedia

Wikipedia : [https://en.wikipedia.org/wiki/Mankind\\_Pharma](https://en.wikipedia.org/wiki/Mankind_Pharma)

Moneycontrol. Financial Charts:

Balance Sheet: <http://www.moneycontrol.com/financials/mankindpharma/balance-sheetVI/MP22#MP22>

Profit and Loss Account: <http://www.moneycontrol.com/financials/mankindpharma/profit-lossVI/MP22#MP22>

Cash Flow statement: <http://www.moneycontrol.com/financials/mankindpharma/cash-flowVI/MP22#MP22>

This should cover your citation needs for the sources of information you used in preparing the financial documents. If you have specific URLs for the exact pages you referenced, including those can make your citations even more precise.

## ANNEXURE

**Table 5.1 : Balance Sheet of MANKIND PHARMA**

### Balance Sheet of MANKIND

## PHARMA

	2024	2023	2022	2021	2020
<b>EQUITIES AND LIABILITIES</b>					
<b>SHAREHOLDER'S FUNDS</b>					
Equity Share Capital	40.06	40.06	40.06	40.06	40.06
<b>TOTAL SHARE CAPITAL</b>	<b>40.06</b>	<b>40.06</b>	<b>40.06</b>	<b>40.06</b>	<b>40.06</b>
Reserves and Surplus	9583.75	7741.85	6028.72	4654.21	3611.39
<b>TOTAL RESERVES AND SURPLUS</b>	<b>9583.75</b>	<b>7741.85</b>	<b>6028.72</b>	<b>4654.21</b>	<b>3611.39</b>
<b>TOTAL SHAREHOLDERS FUNDS</b>	<b>9623.81</b>	<b>7783.91</b>	<b>6068.77</b>	<b>4734.27</b>	<b>3651.45</b>
<b>NON-CURRENT LIABILITIES</b>					
Long Term Borrowings	5.95	0	2.44	0	0
Deferred Tax Liabilities (Net)	71.59	35.85	35.71	0	0
Other Long Term Liabilities	11.21	23.4	15.21	10.77	17.47
Long Term Provisions	111.79	88.87	62.65	56.39	46.41
<b>TOTAL NON-CURRENT LIABILITIES</b>	<b>200.54</b>	<b>148.12</b>	<b>116.06</b>	<b>67.15</b>	<b>63.89</b>
<b>CURRENT LIABILITIES</b>					
Short Term Borrowings	2.62	0	685.45	95	0
Trade Payables	849.52	801.96	924.38	594.08	487.23
Other Current Liabilities	368.12	322.53	383.04	293.04	159.31
Short Term Provisions	373.11	294.59	234.63	186.79	160.23
<b>TOTAL CURRENT LIABILITIES</b>	<b>1593.38</b>	<b>1419.09</b>	<b>2228.01</b>	<b>1078.91</b>	<b>815.77</b>
<b>TOTAL CAPITAL AND LIABILITIES</b>	<b>11417.71</b>	<b>9371.12</b>	<b>8412.85</b>	<b>5800.33</b>	<b>4531.11</b>
<b>ASSETS</b>					
<b>NON-CURRENT ASSETS</b>					
Tangible Assets	3591.92	1435.81	1019.87	965.38	917.35
Intangible Assets	0	1701.08	1841.27	16.58	21.9
Capital Work-In-Progress	0	437.83	355.28	165.51	143.93
Other Assets	0	5.32	5.38	5.46	5.51
<b>FIXED ASSETS</b>	<b>3591.92</b>	<b>3637</b>	<b>3273.08</b>	<b>1152.98</b>	<b>1092.39</b>
Non-Current Investments	2190.62	2040.76	1760.67	1500.86	1389.51
Deferred Tax Assets (Net)	0	0	0	13.04	21.05
Long Term Loans And Advances	8.74	0	0	0	0
Other Non-Current Assets	67.51	176.45	122.32	129.47	79.56
<b>TOTAL NON-CURRENT ASSETS</b>	<b>5858.79</b>	<b>5854.21</b>	<b>5156.07</b>	<b>2790.35</b>	<b>2582.5</b>
<b>CURRENT ASSETS</b>					

Current Investments	2238.51	3061.47	387.77	896.09	294.15
Inventories	1075.59	1032.22	1225.79	826.91	533.48
Trade Receivables	749.47	492.44	517.29	359.37	418.62
Cash And Cash Equivalents	761.01	156.35	71.19	476.95	197.05
Short Term Loans And Advances	39.92	98.34	145.75	227.37	211.88
Other Current Assets	693.42	677.09	906.98	293.75	192.51
<b>TOTAL CURRENT ASSETS</b>	<b>5558.92</b>	<b>3516.91</b>	<b>3256.78</b>	<b>3089.98</b>	<b>1948.6</b>
<b>TOTAL ASSETS</b>	<b>11417.71</b>	<b>9371.12</b>	<b>8412.85</b>	<b>5880.33</b>	<b>4531.11</b>

**Table 5.2 : Profit and Loss account of MANKIND PHARMA**

**Profit and loss account of  
MANKIND PHARMA**

	2024	2023	2022	2021	2020
<b>INCOME</b>					
<b>REVENUE FROM OPERATIONS [GROSS]</b>	<b>9264.81</b>	<b>8120.57</b>	<b>7240.88</b>	<b>5486.16</b>	<b>4730.15</b>
Less: Excise/Service Tax/Other Levies	0	0	0	0	0
<b>REVENUE FROM OPERATIONS [NET]</b>	<b>9264.81</b>	<b>8120.57</b>	<b>7240.88</b>	<b>5486.16</b>	<b>4730.15</b>
<b>TOTAL OPERATING REVENUES</b>	<b>9264.81</b>	<b>8127.15</b>	<b>7257.04</b>	<b>5329.6</b>	<b>4794.81</b>
Other Income	266.34	162.78	162.75	143.08	53.85
<b>TOTAL REVENUE</b>	<b>9531.15</b>	<b>8289.94</b>	<b>7419.77</b>	<b>5577.68</b>	<b>4888.25</b>
<b>EXPENSES</b>					
Cost Of Materials Consumed	861.74	711.05	772.24	494.53	434.37
Purchase Of Stock-In Trade	2071.92	1865.82	2014.37	1543.89	1183.55
Operating And Direct Expenses	0	0	0	0	0
Changes In Inventories Of FG, WIP And Stock-In Trade	-25.36	-287.89	-353.01	-254.75	-44.51
Employee Benefit Expenses	1983.1	1701.38	1443.83	1106.14	991.47
Finance Costs	14.57	27.75	43.83	7.98	10.82
Depreciation And Amortisation Expenses	317.61	269.58	120.58	75.19	61.77
Other Expenses	2040.3	1883.64	1578.99	1267	936.57
<b>TOTAL EXPENSES</b>	<b>7271.88</b>	<b>6727.1</b>	<b>5622.33</b>	<b>4237.47</b>	<b>3621.34</b>
<b>PROFIT/LOSS BEFORE EXCEPTIONAL EXTRAORDINARY ITEMS AND TAX</b>	<b>2259.27</b>	<b>1562.84</b>	<b>1797.44</b>	<b>1440.21</b>	<b>1264.92</b>
Exceptional Items	0	0	0	0	0
<b>PROFIT/LOSS BEFORE TAX</b>	<b>2259.27</b>	<b>1562.84</b>	<b>1797.44</b>	<b>1440.21</b>	<b>1264.92</b>
<b>TAX EXPENSES-CONTINUED OPERATIONS</b>					

Current Tax	436.16	296	399.54	344.89	316.54
Less: MAT Credit Entitlement	0	0	0	0	0
Deferred Tax	0	90.3	49.05	8.64	35.31
Tax For Earlier Years	0	-11.72	11.74	2.1	5.23
<b>TOTAL TAX EXPENSES</b>	<b>436.16</b>	<b>274.58</b>	<b>462.41</b>	<b>355.43</b>	<b>306.7</b>
<b>PROFIT/LOSS AFTER TAX AND BEFORE EXTRAORDINARY ITEMS</b>	<b>1823.41</b>	<b>1248.26</b>	<b>1335.13</b>	<b>1084.37</b>	<b>958.23</b>
<b>PROFIT/LOSS FROM CONTINUING OPERATIONS</b>	<b>1823.41</b>	<b>1248.26</b>	<b>1335.13</b>	<b>1084.37</b>	<b>958.23</b>
<b>PROFIT/LOSS FOR THE PERIOD</b>	<b>1823.41</b>	<b>1248.26</b>	<b>1335.13</b>	<b>1084.37</b>	<b>958.23</b>
<b>OTHER ADDITIONAL INFORMATION</b>					
<b>EARNINGS PER SHARE</b>					
Basic EPS (Rs.)	45.52	31.16	33.33	27.07	23.52
Diluted EPS (Rs.)	45.45	31.16	33.33	27.07	23.92
<b>VALUE OF IMPORTED AND INDIGENOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS</b>					
Imported Raw Materials	0	0	0	0	0
Indigenous Raw Materials	0	0	0	0	0
<b>STORES, SPARES AND LOOSE TOOLS</b>					
Imported Stores And Spares	0	0	0	0	0
Indigenous Stores And Spares	0	0	0	0	0
<b>DIVIDEND AND DIVIDEND PERCENTAGE</b>					
Equity Share Dividend	0	0	0	0	902.44
Tax On Dividend	0	0	0	0	61.82
Equity Dividend Rate (%)	0	0	0	0	75

**Table 5.3 : Cash Flow Statement of MANKIND PHARMA**

**Cash Flow Statement of  
MANKIND PHARMA**

2024      2023      2022      2021      2020



<b>NET PROFIT/LOSS BEFORE EXTRAORDINARY ITEMS AND TAX</b>	<b>2253.57</b>	<b>1562.04</b>	<b>1797.54</b>	<b>1440.21</b>	<b>1204.32</b>
Net Cashflow From Operating Activities	1982.07	1798.99	812.39	1022.33	959.61
Net Cash Used in Investing Activities	-1919.12	-1040.61	-1369.34	-1127.16	-395.68
Net Cash Used From Financing Activities	-8.68	-710.41	578.92	88.87	-558.91
Foreign Exchange Gains / Losses	-0.1	0	0	0	0
Adjustments On Amalgamation Merger Demerger Others	0	0	0	0	0
<b>NET INC/DEC IN CASH AND CASH EQUIVALENTS</b>	<b>55.07</b>	<b>47.96</b>	<b>21.87</b>	<b>-15.96</b>	<b>5.02</b>
Cash And Cash Equivalents Begin of Year	134.13	86.17	22.58	77.5	72.48
Cash And Cash Equivalents End Of Year	189.2	134.13	44.45	61.53	77.5